Metabolic Dysfunction-associated Steatotic Liver Disease– related Hepatocellular Carcinoma: Current Research Insights
10.52927/jdcr.2024.12.3.184
- Author:
Ho Soo CHUN
1
;
Minjong LEE
;
Tae Hun KIM
Author Information
1. Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea
- Publication Type:REVIEW ARTICLE
- From:
Journal of Digestive Cancer Research
2024;12(3):184-194
- CountryRepublic of Korea
- Language:English
-
Abstract:
The global increase in the incidence of metabolic disorders is increasing the burden of nonalcoholic fatty liver disease (NAFLD) progression and NAFLD-related hepatocellular carcinoma (HCC) development; urgent measures are required to reduce this burden. The metabolic aspects of NAFLD led to the proposal to rename this condition as metabolic dysfunction-associated steatotic liver disease (MASLD). Diagnosis of MASLD, unlike that of NAFLD, requires the presence of at least one cardiometabolic risk factor (CMRF), creating a new focus on these factors, although the vast majority of patients with NAFLD meet the criteria for MASLD. In this article, we therefore review the current understanding of MASLD-related HCC, such as the epidemiology, risk factors with a particular focus on CMRFs, surveillance strategies, and risk stratification models.
